Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

EP: 1.Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

EP: 2.Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

EP: 3.Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

EP: 4.Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

EP: 5.Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

EP: 6.Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer

Now Viewing

EP: 7.Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

EP: 8.Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

EP: 9.Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

EP: 10.ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

EP: 11.Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

EP: 12.Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

Video content above is prompted by the following:

Treatment options post progression on CDK4/6i + ET

• What is your overall perception on the class of oral SERDs? How will they continue to impact the treatment landscape?
• What are your perceptions on efficacy and safety data? What has your experience been in practice with:
  • Elacestrant
    • ASCO 2024 #1071: Real-world (RW) elacestrant use patterns and therapeutic outcomes.
    • ASCO 2024 #1064: Elacestrant plus abemaciclib Preliminary data from ELECTRA
    • ASCO 2024 #1069: Elacestrant in various combinations: Preliminary data from ELEVATE
    • Bardia Cancer Res 2023: GS3-01 EMERALD phase 3 trial of elacestrant vs endocrine therapy: Updated results by duration of prior CDK4/6i in metastatic setting